How Shenandoah Oncology became a blueprint for compassion and turned patient feedback into a lifeline.
Hope in Action
Learn how McKesson is turning hope into reality for patients in the communities we serve.
Read Time: Less than 1 minute
We believe in the power of hope to transform lives and unlock the future of healthcare. It drives us every day, in all that we do, to advance health outcomes for all. We strive to push the boundaries of what's next, leveraging the latest technologies and innovations to help solve, support and unravel healthcare’s biggest challenges.
Together, with our partners, we’re committed to bringing hope to the patients and communities we serve. When hope becomes reality, there’s no stopping us.
Learn more about how we’re helping transform patients’ lives in the video above.
Related Stories
How community oncology clinics are helping break down barriers to care.
How Biopharma and community oncology are working together to solve healthcare’s toughest challenges and build a more resilient future for cancer care.
Meeting the demands of ultra-sensitive treatments with purpose-built storage, automation and pharmacy integration
In the third episode of our Always Advancing video series, learn how precision and personalized medicine are transforming cancer care – expanding access to clinical trials and novel treatments in communities.
Using McKesson Compile’s analytics to transform how patients with rare blood disorders access specialized care across Indiana.
InspiroGene by McKesson helps patients with rare and severe diseases access innovative cell and gene therapies through personalized support at every step of their journey.
In the fourth episode of our Always Advancing video series, discover how InspiroGene by McKesson partners with biopharma to expand patient access to advanced therapies.
Explore the latest trends shaping the future of cell and gene therapy and learn what’s needed to ensure innovation reaches patients.
In the second episode of our Always Advancing series, we explore how McKesson and biopharma are breaking barriers to accelerate access to lifesaving therapies.